









Markets
/
Stocks
/
nasdaq-bmrn
/

BioMarin Pharmaceutical Inc

BMRN

View Detailed Chart

58.140USD

+0.290+0.50%

Close 08/01, 16:00（ET）Quotes delayed by 15 min

11.15BMarket Cap

21.28P/E TTM



BioMarin Pharmaceutical Inc

58.140

+0.290+0.50%

Overview Company Financials

Financials

Intraday

30m

Today

+0.50%

5 Days

-1.47%

1 Month

+1.11%

6 Months

-6.89%

Year to Date

-11.55%

1 Year

-30.95%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 29 analysts

BUY

Current Rating

95.594

Target Price

64.42%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

BioMarin Pharmaceutical Inc

BMRN

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(7)

Neutral(4)

Buy(2)

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.091

Neutral

RSI(14)

51.018

Neutral

STOCH(KDJ)(9,3,3)

43.043

Neutral

ATR(14)

1.523

Low Volatility

CCI(14)

-70.624

Neutral

Williams %R

57.966

Sell

TRIX(12,20)

0.148

Sell

StochRSI(14)

29.249

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

58.234

Sell

MA10

58.537

Sell

MA20

58.313

Sell

MA50

57.190

Buy

MA100

60.563

Sell

MA200

63.432

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Ticker SymbolBMRN

CompanyBioMarin Pharmaceutical Inc

CEOMr. Alexander Hardy

Websitehttps://www.biomarin.com/